Related Experiment Videos
Cerivastatin-induced rhabdomyolysis: 11 case reports
Susan L Ravnan1, Christy Locke, William P Yee
1University of the Pacific Thomas J. Long School of Pharmacy and Health Sciences, Stockton, California, USA. sravnan@chw.edu
Pharmacotherapy
|April 10, 2002
Abstract:
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are a frequently prescribed class of drugs that are generally well tolerated by most patients. A rare, yet serious side effect associated with these drugs is rhabdomyolysis. Although all HMG-CoA reductase inhibitors can cause this adverse effect, prevalence may differ among specific agents. Over a 16-month period, in three hospitals, 11 patients experienced cerivastatin-induced rhabdomyolysis, but no cases of rhabdomyolysis associated with any other HMG-CoA reductase inhibitors were reported.